Clinical Factors and Cumulative Smoking Burden Associated with Anti-TNF Switching in Radiographic Axial Spondyloarthritis: A Real-World Cohort Study
- 1Department of Internal Medicine, Division of Rheumatology, Trakya University Faculty of Medicine, 22030 Edirne, Türkiye
- 2Department of Hematology, Edirne Sultan 1. Murat State Hospital, 22030 Edirne, Türkiye
- 3Department of Rheumatology, İskenderun Gelisim Hospital, 31200 Hatay, Türkiye
Abstract
Background/Objectives: Anti-tumor necrosis factor (anti-TNF) switching remains common in radiographic axial spondyloarthritis (r-axSpA). We aimed to evaluate cumulative smoking burden and clinical factors associated with anti-TNF switching. Methods: This retrospective single-center cohort included 212 patients with r-axSpA. Clinical data were collected from medical records. Bivariate comparisons, Kaplan–Meier analysis and multivariable Cox regression assessed switching, with a cause-specific sensitivity analysis for lack-of-response switching. Results: Eighty patients (37.7%) switched initial anti-TNF agent, including 70 (87.5%) for lack of response. While the global comparison of smoking status was nonsignificant (p = 0.105), exploratory unadjusted comparisons of current smokers versus former and never-smokers combined showed associations with all-cause (p = 0.035) and lack-of-response switching (p = 0.012). In adjusted Cox analysis, cumulative smoking burden was associated with increased switching hazard (HR 1.025 per pack-year, 95% CI 1.011–1.039; p < 0.001), alongside peripheral articular involvement (HR: 2.0, 95% CI 1.216–3.296, p = 0.006), higher BASDAI at anti-TNF initiation (HR: 1.02, 95% CI 1.004–1.029, p = 0.007) and later calendar year of treatment initiation (HR: 1.24, 95% CI 1.107–1.394, p < 0.001). Smoking burden >20 pack-years was associated with a higher adjusted switching hazard compared with never-smokers (HR 3.54, 95% CI 2.081–6.033; p < 0.001). Among ever-smokers, Kaplan–Meier comparisons showed shorter drug survival with >20 versus ≤10 and >10–20 pack-years (both p < 0.001). Conclusions: Cumulative smoking burden was associated with an increased hazard of anti-TNF switching, particularly among patients with >20 pack-years. Quantifying smoking exposure may provide additional information beyond smoking status alone.
Related
- Vigorous physical activity and physical function are strongly associated with better health in patients with long-standing radiographic axial spondyloarthritis
- Lower-Limb Muscle Architecture and Strength in Men with Radiographic Axial Spondyloarthritis: A Cross-Sectional Ultrasound Study
- Differentiation of axial spondyloarthritis-related lesions from degenerative lesions on Na[18F]Fluoride PET/CT in a longitudinal dataset of patients with radiographic axial spondyloarthritis
- Impact of bimekizumab on CANDEN spinal MRI inflammation and structural lesions in radiographic axial spondyloarthritis: 2-year phase 3 results
- Clinical Factors Associated with Diagnostic Delay in Axial Spondyloarthritis in Saudi Arabia: A Retrospective Cohort Study.
BibTeX
@article{yigitbasi2026clinical,
title = {{Clinical Factors and Cumulative Smoking Burden Associated with Anti-TNF Switching in Radiographic Axial Spondyloarthritis: A Real-World Cohort Study}},
author = {Ahmet Yigitbasi and Baris Yilmazer},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15218208},
url = {https://www.mdpi.com/2077-0383/15/21/8208},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Clinical Factors and Cumulative Smoking Burden Associated with Anti-TNF Switching in Radiographic Axial Spondyloarthritis: A Real-World Cohort Study
AU - Ahmet Yigitbasi
AU - Baris Yilmazer
PY - 2026
DA - 2026/10/22
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15218208
UR - https://www.mdpi.com/2077-0383/15/21/8208
AB - Background/Objectives: Anti-tumor necrosis factor (anti-TNF) switching remains common in radiographic axial spondyloarthritis (r-axSpA). We aimed to evaluate cumulative smoking burden and clinical factors associated with anti-TNF switching. Methods: This retrospective single-center cohort included 212 patients with r-axSpA. Clinical data were collected from medical records. Bivariate comparisons, Kaplan–Meier analysis and multivariable Cox regression assessed switching, with a cause-specific sensitivity analysis for lack-of-response switching. Results: Eighty patients (37.7%) switched initial anti-TNF agent, including 70 (87.5%) for lack of response. While the global comparison of smoking status was nonsignificant (p = 0.105), exploratory unadjusted comparisons of current smokers versus former and never-smokers combined showed associations with all-cause (p = 0.035) and lack-of-response switching (p = 0.012). In adjusted Cox analysis, cumulative smoking burden was associated with increased switching hazard (HR 1.025 per pack-year, 95% CI 1.011–1.039; p < 0.001), alongside peripheral articular involvement (HR: 2.0, 95% CI 1.216–3.296, p = 0.006), higher BASDAI at anti-TNF initiation (HR: 1.02, 95% CI 1.004–1.029, p = 0.007) and later calendar year of treatment initiation (HR: 1.24, 95% CI 1.107–1.394, p < 0.001). Smoking burden >20 pack-years was associated with a higher adjusted switching hazard compared with never-smokers (HR 3.54, 95% CI 2.081–6.033; p < 0.001). Among ever-smokers, Kaplan–Meier comparisons showed shorter drug survival with >20 versus ≤10 and >10–20 pack-years (both p < 0.001). Conclusions: Cumulative smoking burden was associated with an increased hazard of anti-TNF switching, particularly among patients with >20 pack-years. Quantifying smoking exposure may provide additional information beyond smoking status alone.
SN - 2077-0383
ER -